stockrowInteger Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.
- Revenue
- −3.86%
- EPS
- −61.0%
- Free cash flow
- −65.2%
- Total debt
- +4.06%
Quarter to September 2026, against a year earlier
Follow ITGR
Alert me
Integer Holdings Corporation (ITGR) Revenue
Integer Holdings Corporation's revenue for fiscal 2025 was $1.9B, up 7.98% from $1.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.8B. Over the past ten years it has ranged from $800.4M (fiscal 2015) to $1.9B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Integer Holdings Corporation ranks 20th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.9B | 7.98% |
| FY2024 | $1.7B | 10.35% |
| FY2023 | $1.6B | 16.85% |
| FY2022 | $1.3B | 9.02% |
| FY2021 | $1.2B | 13.75% |
| FY2020 | $1.1B | (14.68%) |
| FY2019 | $1.3B | 3.55% |
| FY2018 | $1.2B | 6.95% |
| FY2017 | $1.1B | 5.63% |
| FY2016 | $1.1B | 34.37% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $449.7M | (3.11%) |
| Jun 2026 | $464.1M | 5.58% |
| Mar 2026 | $439.6M | (6.88%) |
| Dec 2025 | $472.1M | 0.93% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ITGR Integer Holdings Corporation | $1.8B |
| LIVN LivaNova PLC compare | $1.5B |
| HAE Haemonetics Corporation compare | $1.4B |
| NEOG Neogen Corporation compare | $884.0M |
| IRTC iRhythm Holdings, Inc. compare | $854.0M |
| TMDX TransMedics Group, Inc. compare | $727.7M |
| UFPT UFP Technologies, Inc. compare | $649.5M |
| TXG 10x Genomics compare | $616.9M |
| AXGN AxoGen, Inc. compare | $266.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ITGR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement